Navigation Links
Use Of Cryoablation For Treatment Of Breast Cancer Shows Promising Results
Date:5/7/2013

CHICAGO, May 7, 2013 /PRNewswire/ -- Dr. Eisuke Fukuma has treated 58 breast cancer patients with cryoablation over the last 6 years under a research protocol at Kameda Medical Center in Japan.  As of today, none of the patients have had a tumor reoccur or distant metastases. By this non-surgical treatment, Dr. Fukuma's patients avoid the risks and potential cosmetic impact of major breast cancer surgery.  The fact that none have had recurrences, suggests that, with further study, Cryoablation may offer significant, minimally-invasive breast health options.

(Photo: http://photos.prnewswire.com/prnh/20130507/CL09547)

Cryoablation is the technique of using extreme cold to destroy tissue.  It has been used for years in medical applications like dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors.

Eisuke Fukuma , MD, PhD, is Chairman of Breast Center at Kameda Medical Center in Kamogawa  City, Chiba, Japan.  Since 2006, his team has been developing cryoablation under image-guidance as a nonsurgical treatment for small breast cancer.

Dr. Fukuma's most recent 20 patients added to the clinical trial were treated using the IceSense3 Cryoablation system from IceCure Medical. While mainstream cancer treatment still requires significant research, the IceSense3 system is widely available in the US for the treatment of benign breast disease.  The procedure usually takes about 10-15 minutes; with no pain and virtually no scar (no sutures are required). As with a needle biopsy, many women can return to work or their normal activity quickly.

Dr. Fukuma previewed his next steps in research, which include expanding his research for larger tumors using the IceSense3, to a packed room of physicians and researchers at the 2013 conference of the American Society of Breast Surgeons (ASBrS).  To determine if nonsurgical cryoablation is an acceptable treatment for patients with small breast cancer, "we have to study a larger number of patients for a longer time period," remarks Dr. Fukuma.

Because of its procedural, clinical, and cosmetic results, Cryoablation garnered high level of attention at the conference.  Author of several pivotal studies on Cryoablation of benign tumors, Dr. Cary Kaufman also spoke about its use in breast cancer, adding that it has potential immunological benefits.

"We are extremely excited with the results presented by Dr. Fukuma," stated Hezi Himelfarb , President and CEO of IceCure Medical. "IceSense3 cryoablation system will continue to have major role in Dr. Fukuma's study towards providing less invasive and better cosmetic options for patients."

The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA approval for benign and malignant breast disease.

About IceCure Medical

IceCure Medical, Inc.is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. To learn more about IceCure and Cryoablation for Breast Disease, please find us on the web at www.IceCure-Medical.com.  To learn about patient advocacy efforts follow us @CoverCryo on Twitter and BreastHealthOptions on Facebook.

For more information, contact
Will Irby
IceCure Medical, Inc.
(901) 237-4630
wirby@icecure-medical.com


'/>"/>
SOURCE IceCure Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
2. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
3. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
4. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
5. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
6. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
7. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
8. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
9. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
10. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017  Bioness, Inc., the leading provider of ... first series of successful StimRouter Neuromodulation System implantations in ... Center (Nijmegen, Netherlands ), ... ), and Kliniek Park Leopold Chirec ( ... Bioness plans to further support clinicians across the continent ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 According ... (Spectroscopy, Chromatography), Measurement (On-Line, In-Line, At-Line), Products and Services (Analyzers, Probes & ... to 2021", published by MarketsandMarkets, the global market is poised to reach ... a CAGR of 13.3% from 2016 to 2021. ... ...
(Date:2/22/2017)... SEATTLE , Feb. 22, 2017 ... translational development of novel immune modulating therapies, today ... the a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust ... preclinical pain models. The study also establishes the ... the treatment of chronic pain. The findings were ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... In a recent article ... context (age, illness and life choices) should be dissociated from medical errors and ... In addition, all too often, studies regarding health system performance in other countries, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... for supply chain management (SCM) and spend management, today announced that Keppel Corporation ... time, and simplify expense tracking. , “We are excited to announce the ...
(Date:2/21/2017)... ... February 22, 2017 , ... Author Michèle Wolff has ... for every household and family to know all about it for optimal health. Wanting ... the release of “ Detox, Digestive and Wellness Solutions ” (published by Balboa Press ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... five new hospital-grade power extension cords that meet the most current standards. , ... 2012 edition of the National Fire Protection Association (NFPA) 101 – Life Safety ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... Doctors ... , CA, directed by Dr. Kendell Mendonca , to its growing network of ... compensation injuries including injuries stemming from car accidents such as whiplash, back pain, neck ...
Breaking Medicine News(10 mins):